Table 2 Characteristics of studies
From: Reconceptualizing autonomic function testing in migraine: a systematic review and meta-analysis
Reference | Boiardi et al. [4] | Havanka-Kanniainen et al. [51] | Havanka-Kanniainen et al. [52] | Havanka-Kanniainen et al. [53] | Havanka-Kanniainen et al. [54] | Pogacnik et al. [56] | Qavi et al. [57] |
|---|---|---|---|---|---|---|---|
Year | 1988 | 1986 | 1986 | 1987 | 1988 | 1993 | 2023 |
Country | Italy | Finland | Finland | Finland | Finland | Slovenia | India |
Study design | Case–control | Case–control | Case–control | Clinical Trial | Case–control | Case–control | Case-control |
N (female), MP/HC | 102 (50), 68/34 | 20 (18), 10/10 | 74 (55), 49/25 | 40 (15), 21/19 | 273 (192), 188/85 | 107 (67), 62/45 | 50 (36), 50/50 |
Age mean (SD) MP/HC | 37.9 (1.7)/35.4 (1.6) | 41.5 (8.6)/41.4 (4.6) | 17.4 (2.8)/17.8 (3.9) | 40.8 (8.8)/36.4 (6.8) | 30.4 (12.7)/28.3 (11.3) | 36.5 (7.6)/35.6 (8.2) | 27.7 (8.3)/ 28.3 (8.7) |
Age Range MP/HC | N/A | 24–56/(N/A) | 11–22/10–22 | 21–54/(N/A) | 11–69/10–61 | 21–50/22–49 | 15–50/15–50 |
Diagnosis Criteria | AHC-CoH | AHC-CoH | AHC-CoH | AHC-CoH | AHC-CoH | IHS | ICHD-3 |
Migraine type | COM | COM & CLM | COM & CLM | COM & CLM | COM & CLM | MwA & MoA | MwA & MoA |
Aura | Not specified | Not specified | With and without | Not specified | With and without | With and without | With and without |
Attack Frequency | Not specified | Episodic | Episodic | Episodic | Episodic | Not specified | Episodic |
Other Comorbidities | None | Not specified | None | None | None | Not specified | None |
Therapy specified | Not specified | None | None | Nimodipine | None | None | None |